Aminoglycoside elimination in extended duration hemodialysis [2]

Annals of Pharmacotherapy

Volumn 40, Issue 4, 2006, Pages 783-784

  Dager, William E ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN; TOBRAMYCIN;

ACUTE KIDNEY FAILURE; ARTIFICIAL KIDNEY; BLOOD FLOW VELOCITY; CASE REPORT; COMPARTMENT MODEL; CONTINUOUS HEMODIAFILTRATION; CRITICALLY ILL PATIENT; DEVICE; DRUG BLOOD LEVEL; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; EXTENDED DAILY DIALYSIS; HEMODIALYSIS; HUMAN; LETTER; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY;

AMINOGLYCOSIDES; HALF-LIFE; HUMANS; KIDNEY FAILURE, ACUTE; METABOLIC CLEARANCE RATE; RENAL DIALYSIS; TIME FACTORS;

EID: 33646232249     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G420     Document Type: Letter

References (3)

1. Kumar VA, Craig M, Depner TA, Yeun JY. Extended daily dialysis: a new approach to renal replacement for acute renal failure in the intensive care unit. Am J Kidney Dis 2000;36:294-300.
2. Manley HJ, Bailie GR, McClaran ML, Bender WL. Gentamicin pharmacokinetics during slow daily home hemodialysis. Kidney Int 2003;63:1072-8.
3. Dager WE, King JH. Aminoglycosides in intermittent hemodialysis: pharmacokinetic and individual dosing observations. Ann Pharmacother 2006;40:9-14. Epub 6 Dec 2005. DOI 10.1345/aph.1G064